The Complainant, a company with its seat in Ingelheim, Germany, is active in the pharmaceutical industry. It was founded in the 19th century and now has activities at a global scale, with over 50,000 employees. It produces and markets a broad range of human and animal products, including SPIRIVA, a formulation with the active ingredient tiotropium bromide used in the treatment of adult humans with chronic obstructive pulmonary disease. It promotes this product through a website at <www.spiriva.com>, the domain name being first registered on 15 February 1999 and duly renewed since then.
The Respondent, an individual with an incomplete address in Nanchong, Sichuan, China, registered the disputed domain name on 8 December 2021.
|